Search Result

Results for "

analgesic action

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Adenosine Receptor (1) Adrenergic Receptor (1) Angiotensin Receptor (2) Antibiotic (1) Apoptosis (1) Bacterial (1) Biochemical Assay Reagents (1) CGRP Receptor (1) COX (7) Drug Derivative (1) Endogenous Metabolite (2) Environmental Pollutants (1) Histamine Receptor (1) Isotope-Labeled Compounds (3) Lipoxygenase (1) Phytohormone (1) PI3K (1) Reference Standards (2) Sigma Receptor (1) Sodium Channel (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Endocrinology (4) Infection (1) Inflammation/Immunology (8) Metabolic Disease (1) Neurological Disease (10)

By Targets:

5-HT Receptor (1)

Adenosine Receptor (1)

Adrenergic Receptor (1)

Angiotensin Receptor (2)

Antibiotic (1)

Apoptosis (1)

Bacterial (1)

Biochemical Assay Reagents (1)

CGRP Receptor (1)

COX (7)

Drug Derivative (1)

Endogenous Metabolite (2)

Environmental Pollutants (1)

Histamine Receptor (1)

Isotope-Labeled Compounds (3)

Lipoxygenase (1)

Phytohormone (1)

PI3K (1)

Reference Standards (2)

Sigma Receptor (1)

Sodium Channel (1)

By Research Areas:

Cancer (6)

Cardiovascular Disease (1)

Endocrinology (4)

Infection (1)

Inflammation/Immunology (8)

Metabolic Disease (1)

Neurological Disease (10)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-18342

Diflunisal 1 Publications Verification MK-647	COX	Inflammation/Immunology Cancer
Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

HY-13106

Olodanrigan 4 Publications Verification EMA401; PD-126055; (S)-EMA400	Angiotensin Receptor	Cardiovascular Disease Neurological Disease Endocrinology
Olodanrigan (EMA401) is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. It is under development as a neuropathic pain therapeutic agent. Olodanrigan (EMA401) analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-121222

alpha-Bisabolol	PI3K Apoptosis	Cancer
alpha-Bisabolol, an orally active sesquiterpene alcohol, induces cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. alpha-Bisabolol exerts a protective action against Cisplatin (HY-17394)-induced nephrotoxicity by mitigating inflammation and oxidative stress through the inhibition of NFκB activation. alpha-Bisabolol exhibits anti-inflammatory, analgesic, antibiotic and anticancer activities .

HY-B0619

Zaltoprofen 2 Publications Verification CN100	COX	Inflammation/Immunology
Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC₅₀s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain .

HY-18342S

Diflunisal-d3 MK-647-d₃	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Diflunisal-d₃ is the deuterium labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

HY-13106A

Olodanrigan sodium EMA401 sodium; PD-126055 sodium	Angiotensin Receptor	Neurological Disease Endocrinology
Olodanrigan (EMA401) sodium is a highly selective, orally active, peripherally restricted angiotensin II type 2 receptor (AT2R) antagonist. Olodanrigan sodium is under development as a neuropathic pain therapeutic agent. Olodanrigan sodium analgesic action appears to involve inhibition of augmented AngII/AT2R induced p38 and p42/p44 MAPK activation, and hence inhibition of DRG neuron hyperexcitability and sprouting of DRG neurons .

HY-19699

1-Naphthylacetamide NAAM; 1-Naphthaleneacetamide; α-Naphthylacetamide	Environmental Pollutants Phytohormone	Neurological Disease Endocrinology
1-Naphthylacetamide is an orally active nonsteroidal anti-inflammatory agent (NAIA) and also an indole-type auxin plant growth regulator. 1-Naphthylacetamide inhibits inflammatory response-related pathways and modulates plant hormone signaling, exhibiting anti-inflammatory, local anesthetic, antispasmodic, analgesic, and diuretic activities. 1-Naphthylacetamide promotes plant cell expansion, differentiation, and fruit enlargement. Additionally, 1-Naphthylacetamide induces central nervous system (CNS) depression in mice, characterized by reduced spontaneous activity, decreased irritability, decreased muscle tone, and attenuated ear-cuff reflex, ipsilateral flexor reflex, and corneal reflex ^[1][2].

HY-U00333

α1 adrenoceptor-MO-1	Adrenergic Receptor	Neurological Disease Endocrinology
α1 adrenoceptor-MO-1, an S enantiomer, has affinity at alpha 1 adrenergic receptor, shows alphalytic activity, and possesses analgesic action; more active than R enantiomer.

HY-P1617

LY 190388	Endogenous Metabolite	Neurological Disease
LY 190388 is a penicillamine-containing enkefa peptide analog with μ receptor agonist activity. LY 190388 showed analgesic effect in inhibiting the writhing response in mice after intracerebroventricular administration. The analgesic effect of LY 190388 is not caused by its δ receptor agonist action, but by its μ receptor agonist activity. When LY 190388 is used together with the δ receptor antagonist ICI 174864, an additive analgesic effect is produced .

HY-174845

Nav1.8-IN-20	Sodium Channel	Neurological Disease
Nav1.8-IN-20 (Compound I) is an orally active and potent voltage-gated sodium channel Nav1.8 inhibitor with an IC₅₀ value of 14 nM. Nav1.8-IN-20 blocks the generation and conduction of action potentials in peripheral nociceptive neurons, exerting analgesic effects. Nav1.8-IN-20 is promising for research of various pain types such as acute pain, chronic pain, inflammatory pain, and neuropathic pain .

HY-18342R

Diflunisal (Standard) MK-647 (Standard)	Reference Standards COX	Inflammation/Immunology Cancer
Diflunisal (Standard) is the analytical standard of Diflunisal. This product is intended for research and analytical applications. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

HY-18342S1

Diflunisal-13C6 MK-647-¹³C₆	Isotope-Labeled Compounds COX	Inflammation/Immunology Cancer
Diflunisal- ¹³C₆ (MK-647- ¹³C₆) is ¹³C labeled Diflunisal. Diflunisal (MK-647) is a salicylate derivative with nonsteroidal anti-inflammatory and uricosuric properties, which is used alone as an analgesic and in rheumatoid arthritis patients. The mechanism of action of diflunisal is as a Cyclooxygenase (COX) Inhibitor.

HY-121886

Bucricaine	Endogenous Metabolite	Neurological Disease
Bucricaine is an anesthetic compound with analgesic activity. Bucricaine is used in clinical anesthesia to reduce pain during surgery. The mechanism of action of Bucricaine involves inhibition of nerve signaling. Bucricaine's applications include local anesthesia and dental anesthesia. Bucricaine is widely used during surgery and other medical procedures to improve patient comfort .

HY-106935A

CGP 29030A	Drug Derivative	Neurological Disease
CGP 29030A is an orally effective and specific analgesic agent. CGP 29030A inhibits nociceptive spinal cord neurons without affecting normal sensory functions. CGP 29030A also inhibits gamma motor neurons, which may be beneficial for studying pain disorders that occur concurrently due to increased motor activity (such as cramp, spasm) .

HY-B0619S1

Zaltoprofen-13C,d3	Isotope-Labeled Compounds COX	Inflammation/Immunology
Zaltoprofen- ¹³C,d₃ is the ¹³C- and deuterium labeled Zaltoprofen. Zaltoprofen (CN100), a non-steroidal anti-inflammatory drug (NSAID), is a preferential and orally active COX-2 inhibitor, with IC₅₀s of 1.3 and 0.34 μM for COX-1 and COX-2, respectively. Zaltoprofen exhibits powerful anti-inflammatory effects as well as an analgesic action on inflammatory pain .

HY-N3074R

Hexahydrofarnesyl acetone (Standard) 6,10,14-Trimethyl-2-pentadecanone (Standard)	Reference Standards Bacterial Antibiotic	Infection Inflammation/Immunology Cancer
alpha-Bisabolol (Standard) is the analytical standard of alpha-Bisabolol. This product is intended for research and analytical applications. alpha-Bisabolol, an orally active sesquiterpene alcohol, induces cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. alpha-Bisabolol exerts a protective action against Cisplatin (HY-17394)-induced nephrotoxicity by mitigating inflammation and oxidative stress through the inhibition of NFκB activation. alpha-Bisabolol exhibits anti-inflammatory, analgesic, antibiotic and anticancer activities .

HY-127141

Cizolirtine citrate E-4018	Adenosine Receptor 5-HT Receptor CGRP Receptor	Neurological Disease
Cizolirtine citrate (E-4018) is an analgesic agent. Cizolirtine citrate has significant analgesic and anti-hyperalgesic action in neuropathic pain models .

HY-19086

SKF-105809	COX Lipoxygenase	Inflammation/Immunology
SKF-105809 is a dual-action inhibitor of lipoxygenase and COX. SKF-105809 inhibits edema and inflammatory cell infiltration in mouse models of ear, paw, and peritoneum inflammation. SKF-105809 inhibits the production of relevant acute-phase reactive proteins in a mouse model of arthritis. SKF-105809 exhibits analgesic activity in a mouse abdominal contraction test and inhibits ulceration. SKF-105809 can be used in research on inflammatory and immune system diseases such as peritonitis and arthritis .

HY-W982689

Fluindarol	Biochemical Assay Reagents	Metabolic Disease
Fluindarol is a phenylindandione derivative and an orally active anticoagulant. Fluindarol acts as a toxicant that induces organ and tissue haemorrhages and liver parenchymal necrosis in rats. Fluindarol exhibits acute and cumulative preclinical toxicity in rats, rabbits, and dogs, with higher toxicity in female rats than male rats. Fluindarol lacks analgesic action, produces only minor blood pressure effects, and does not alter circulation, respiration, CNS, or cardiac activity. Fluindarol is considered too toxic for clinical use based on preclinical data .

HY-181722

σ1R/H3R ligand-1	Sigma Receptor Histamine Receptor	Neurological Disease
σ1R/H3R ligand-1 is a dual σ₁R/H₃R antagonist with a σ₁R K_i of 8.8 nM and an H₃R K_i of 31.2 nM. Through the dual action of simultaneously antagonizing σ1R and H3R, σ1R/H3R ligand-1 exhibits potent dose-dependent analgesic activity in mouse models of visceral pain and neuropathic pain. σ1R/H3R ligand-1 can be used for the research of visceral pain and neuropathic pain .

Cat. No.	Product Name

HY-L130

Non-steroidal Anti-Inflammatory Compound Library	627 compounds
Non-steroidal anti-inflammatory drugs (NSAIDs) are members of a therapeutic drug class with potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. The most prominent NSAIDs are aspirin, ibuprofen, and naproxen. The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX), based on which NSAIDs can be classified into two types: non-selective and COX-2 selective. Most NSAIDs are non-selective and inhibit both COX-1 and COX-2 activity. MCE offers a unique collection of 627 non-steroidal compounds with identified anti-inflammatory activity. MCE non-steroidal anti-inflammatory library is a useful tool for the study of anti-inflammatory drugs and pharmacology.

Non-steroidal Anti-Inflammatory Compound Library

627 compounds

Non-steroidal anti-inflammatory drugs (NSAIDs) are members of a therapeutic drug class with potent anti-inflammatory, analgesic and antipyretic activity, and are among the most widely used drugs worldwide. The most prominent NSAIDs are aspirin, ibuprofen, and naproxen.

The main mechanism of action of NSAIDs is the inhibition of the enzyme cyclooxygenase (COX), based on which NSAIDs can be classified into two types: non-selective and COX-2 selective. Most NSAIDs are non-selective and inhibit both COX-1 and COX-2 activity.

MCE offers a unique collection of 627 non-steroidal compounds with identified anti-inflammatory activity. MCE non-steroidal anti-inflammatory library is a useful tool for the study of anti-inflammatory drugs and pharmacology.

Cat. No.	Product Name	Target	Research Area